Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life

Immunology Letters

Volumn 169, Issue , 2016, Pages 33-40

  Kang, Hyeon Ju ^a,b   Kim, Hye Jin ^a   Cha, Sang Hoon ^a  

^a Kangwon National University   (South Korea)

^b Ahngook Pharm   (South Korea)

Author keywords

Fab; Periplasmic expression; Phage display; Serum albumin; Serum half life

Indexed keywords

HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PROTEIN BINDING; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANTIBODY LIBRARY; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; ISOLATION PROCEDURE; NONHUMAN; PH; PHAGE DISPLAY; PHARMACOKINETIC ASSAY; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; RAT MODEL; ANIMAL; CELL SURFACE DISPLAY; DOG; HALF LIFE TIME; HAPLORHINI; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT;

ANIMALS; CELL SURFACE DISPLAY TECHNIQUES; CROSS REACTIONS; DOGS; HALF-LIFE; HAPLORHINI; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; MICE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN;

EID: 84949920992     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.11.013     Document Type: Article

References (41)

1. Hoogenboom H.R., Chames P. Natural and designer binding sites made by phage display technology. Immunol. Today 2000, 21:371-378.
2. da Silva F.Aires, Corte-Real S., Goncalves J. Recombinant antibodies as therapeutic agents: pathwaysfor modeling new biodrugs. BioDrugs 2008, 22:301-314.
3. Walsh G. Biopharmaceutical benchmarks. Nat. Biotechnol. 2006, 24:769-776.
4. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
5. Rothe C., Urlinger S., Lohning C., Prassler J., Stark Y., Jager U., Hubner B., Bardroff M., Pradel I., Boss M., Bittlingmaier R., Bataa T., Frisch C., Brocks B., Honegger A., Urban M. The human combinatorial antibody library HuCALGOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J. Mol. Biol. 2008, 376:1182-1200.
6. Skerra A., Plückthun A. Assembly of a functional immunoglobulin Fv fragment in E. coli. Science 1988, 240:1038-1041.
7. Better M., Chang C.P., Robinson R.R., Horwitz A.H. E. coli secretion of an active chimeric antibody fragment. Science 1988, 240:1041-1043.
8. Choe M., Webber K.O., Pastan I. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3. Cancer Res. 1994, 54:3460-3467.
9. Kreitman R.J., Chang C.N., Hudson D.V., Queen C., Bailon P., Pastan I. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Int. J. Cancer 1994, 57:856-864.
10. Holzer W., Petersen F., Strittmatter W., Matzku S., von Hoegen I. A fusion protein of IL-8 and a Fab antibody fragments binds to IL-8 receptors and induces neutrophil activation. Cytokine 1996, 8:214-221.
11. Søgaard M., Ohlsson L., Kristensson K., Rosendahl A., Sjoberg A., Forsberg G., Kalland T., Dohlsten M. Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors. Int. J. Oncol. 1999, 15:873-882.
12. Ilbäck N., Gunnarsson K., Persson R., Lindh U., Stålhandske T. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit. Toxicology 2003, 185:161-174.
13. Nelson A.L. Antibody fragments: hope and hype. MAbs 2010, 2:77-83.
14. Entwistle J., Brown J.G., Chooniedass S., Cizeau J., MacDonald G.C. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother. Radiopharm. 2012, 27:582-592.
15. Sleep D., Cameron J., Evans R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 2013, 1830:5526-5534.
16. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 2011, 22:868-876.
17. Dennis M.S., Zhang M., Meng Y.G., Kadkhodayan M., Kirchhofer D., Combs D., Damico L.A. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 2002, 277:35035-35043.
18. Nguyen A., Reyes A.E., Zhang M., McDonald P., Wong W.L.T., Damico L.A., Dennis M.S. The pharmacokinetics of an albumin-binding Fab (AB. Fab) can be modulated as a function of affinity for albumin. Prot. Eng. Des Sel. 2006, 19:291-297.
19. Holt L.J., Basran A., Jones K., Chorlton J., Jespers L.S., Brewis N.D., Tomlinson I.M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 2008, 21:283-288.
20. Walker A., Dunlevy G., Rycroft D., Topley P., Holt L.J., Herbert T., Davies M., Cook F., Holmes S., Jespers L., Herring D. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng. Des. Sel. 2010, 23:271-278.
21. Smith B.J., Popplewell A., Athwal D., Chapman A.P., Heywood S., West S.M., Carrington B., Nesbitt A., Lawson A.D.G., Antoniw P., Eddelston A., Suitters A. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjugate Chem. 2001, 12:750-756.
22. Shimba N., Torigoe H., Takahashi H., Masuda K., Shimada I., Arata Y., Sarai A. Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody. FEBS Lett. 1995, 360:247-250.
23. Carter P., Kelley R.F., Rodrigues M.L., Snedecor B., Covarrubias M., Velligan M.D., Wong W.L., Rowland A.M., Kotts C.E., Carver M.E. High level E. coli expression and production of a bivalent humanized antibody fragment. Biotechnol. (NY) 1992, 10:163-167.
24. Venturi M., Seifert C., Hunte C. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J. Mol. Biol. 2002, 315:1-8.
25. Donzeau M., Knappik A. Recombinant monoclonal antibodies. Methods Mol. Biol. 2007, 378:14-31.
26. Retallack D.M., Jin H., Chew L. Reliable protein production in a Pseudomonas fluorescens expression system. Protein Exp. Purif. 2013, 81:157-165.
27. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, New York, USA. 2nd ed.
28. Joo H., Hur B., Lee K., Song S. s. Cha, Establishment of a reliable dual-vector system for the phage display of antibody fragments. J. Immunol. Methods 2008, 333:24-37.
29. Hur B., Choi H., Song S., Yoon J., Liu L. s. Cha Development of the dual-vector system-III (DVS-III) which facilitates affinity maturation of a Fab antibody via light chain shuffling. Immunol. Lett. 2010, 132:24-30.
30. Choi H., Song S., Yoon J., L Liu, Kim K., Cha S. Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells. Immunol. Lett. 2011, 136:213-220.
31. Costin J.M., Zaitseva E., Kahle K.M., Nicholson C.O., Rowe D.K., Graham A.S., Bazzone L.E., Hogancamp G., Figueroa A., Sierra M., Fong R.H., Yang S.T., Lin L., Robinson J.E., Doranz B.J., Chernomordik L.V., Michael S.F., Schieffelin J.S., Isern S. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J. Virol. 2013, 87:52-66.
32. Smith B.J., Popplewell A., Athwal D., Chapman A.P., Heywood S., West S.M., Carrington B., Nesbitt A., Lawson A.D., Antoniw P., Eddelston A., Suitters A. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjugate Chem. 2001, 12:750-756.
33. Rajpa A., Beyaz N., Haber L., Cappuccilli G., Yee H., Bhatt R.R., Takeuchi T., Lerrner R.A., Crea R. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8466-8471.
34. Thie H., Voedisch B., Dubel S., Hust M., Schirrmann T. Affinity maturation by phage display. Method Mol. Biol. 2009, 525:309-322.
35. Chowdhury P.S., Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 1999, 17:568-572.
36. Magari M., Sawatari T., Kawano Y., Cascalho M., Wabl M., Kanayama N., Hikida M., Ohmori H. Contribution of light chain rearrangement in peripheral B cells to the generation of high-affinity antibodies. Eur. J. Immunol. 2002, 32:957-966.
37. Andersen J.T., Dalhus B., Cameron J., Daba M.B., Plumridge A., Evans L., Brennan S.O., Gunnarsen K.S., Bjørås M., Sleep D., Sandlie I. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun. 2012, 3:610.
38. Gaizutis M., Pesce A.J., Pollak V.E. Renal clearance of human and rat albumins in the rat. Proc. Soc. Exp. Biol. Med. 1975, 148:947-952.
39. Ujhelyi M.R., Robert S. Pharmacokinetic aspect of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin. Pharmacokinet. 1995, 28:483-493.
40. Chadd H., Chamow S.M. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 2001, 12:188-194.
41. Graumann K., Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol. J. 2006, 1:164-186.